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ABSTRACT
Current scientiﬁc publishing uses a selective, slow, and adversarial editorial process to publish a minority of papers
submitted, and thus maximize a journal’s impact factor, a major measure of success. However, the results of many
pharmaceutical industry studies are deemed low priority and are therefore difﬁcult or impossible to publish in
scientiﬁc journals. Society is poorly served because access to the results of these studies is in the public interest.
Archives of Drug Information is an independent, online only journal that will publish papers that are free of bias and
that provide new information about a drug. Articles that would not usually be published by traditional journals, for
example articles reporting negative studies, studies reporting animal toxicity or Phase I human studies, or routine
pharmacokinetic or drug interaction studies are welcome. The editorial process will be rapid and user friendly. The
contents of the journal will be available freely to all. Archives of Drug Information will allow the pharmaceutical
industry to publish the results of studies and make freely accessible to the public the results of research studies that
would otherwise remain unavailable “on-ﬁle.” Making the results of studies available to the public is not only ethical
and good scientiﬁc citizenship, but ultimately, also good business.
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.
interscience.wiley.com/authorresources/onlineopen.html
S
cientiﬁc publishing focuses on the selective
publication of the highest quality articles
appropriate for a particular journal. Acceptance
rates of around 30 percent are common, and pri-
ority is accorded to papers that are hypothesis-
based and of general interest within a particular
scientiﬁc area. The success of a journal is often
judged by its impact factor, thus there is a strong
motivation to selectively publish those articles that
are likely to be cited widely. The current submis-
sion process is an iterative and adversarial one with
reviewers trying to ﬁnd reasons why a paper
should not be published. Many methodologically
sound papers are rejected based on the priority
accorded them by the reviewers and the editor.
This model suits the academic world, but it is
poorly suited to industry.
Current Scientiﬁc Publishing and the
Pharmaceutical Industry
The needs of the pharmaceutical industry are
not met by scientiﬁc journals. Much of the data
produced by industry are descriptive rather than
hypothesis driven, and much of this information is
of interest to only a small number of individuals.
For example, negative studies, or a pharmacoki-
netic study of compound that does not yet have a
name (XYZ 4567) and has a high likelihood of
being withdrawn from development in subsequent
years, are not a high priority for scientiﬁc journals.
The protracted and iterative editorial process,
while suited to an academic environment, is poorly
suited to early drug development studies in an
industry where the emphasis is on presenting the
data rather than on producing a well-argued sci-
entiﬁc package. Thus, one of the reasons so many
industry studies are never published is that much
of the work would not be accepted by scientiﬁc
journals.
Scientiﬁc Publishing and Society
A recent review points out the challenges to the
registration of clinical trials, and draws attention
to an even greater problem—the results of many
clinical trials are never made public [1]. Society is
poorly served because access to the results of
unpublished studies is in the public interest. There
are several reasons for this. First, it will prevent
scientists in drug development from repeating
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have explored. Subjecting humans to studies when
risks, or lack of efﬁcacy, have previously been rec-
ognized, but not made public, is ethically unac-
ceptable [2]. Second, making the results of studies
freely available allows the scientiﬁc world access to
information, and thus the ability to assess risks
and beneﬁts independently. The pharmaceutical
industry has been criticized for not publishing the
results or studies performed in the development of
a drug, particularly when adverse effects were
reported later. Transparency is the best protection
against later allegations that data were deliberately
hidden from the public.
Making the Results of Studies Available
There has been a public demand that the results of
all studies should be made available and placed in
the public domain. Several pharmaceutical compa-
nies and organizations have created databases for
clinical trial results. Many have the following dis-
advantages: they are difﬁcult to search and navi-
gate; the quantity of information provided varies,
but is often only a summary; it is unclear who the
authors of the report are; it is unclear how the
database is curated; there is no external peer
review; and there is a perceived lack of indepen-
dence. Archives of Drug Information seeks to
remedy the obstacles to publication of research
studies about drugs.
About Archives of Drug Information
Archives of Drug Information is an independent,
online-only, peer-reviewed journal that provides
high quality, rapid, efﬁcient publication of original
unbiased scientiﬁc articles about drugs. It makes
available to the public information that other jour-
nals may regard as being of low priority for pub-
lication and of archival interest, and provides free
access to citable and searchable information.
Archives of Drug Information does not charge
readers but authors pay a manuscript fee. The con-
trasts between Archives of Drug Information and
current scientiﬁc literatures are summarized in
Table 1.
What Does Archives of Drug Information Publish?
The Archives publishes papers presenting original
research about drugs. Papers that would be of
low priority for traditional scientiﬁc journals but
are the routine work of drug development, for
example early drug development studies, routine
pharmacokinetic or drug-drug interaction studies,
dose-ﬁnding studies, animal toxicity studies, pilot
studies, and negative clinical studies are welcome.
A broad range of work including cellular, animal
and human studies are of interest, but we do not
publish opinion pieces, meta-analyses or review
articles.
Criteria for Publication in Archives of
Drug Information
To be published, a paper must fulﬁll the following
criteria:
• Present original research about a drug or com-
pound that has not been published elsewhere.
Table 1 Current Scientiﬁc Journals and Archives of Drug Information—differences and similarities
Current journals Archives of Drug Information
Only publish the top 1/3 of papers Publishes suitable papers
Peer review that is adversarial Peer review that aims to avoid bias, ensure quality and
improve an article for readers
Slow, painful and subjective editorial process Rapid, painless and transparent editorial process
Publishes hypothesis-based work Publishes hypothesis-based and descriptive information
Publishes work in a narrow area Publishes a broad range of work about drugs—chemistry,
cell, animal, human studies
Publishes work that is of wide interest Publishes work that may be of limited interest
Emphasis in papers is on the Introduction that sets up the scientiﬁc
rationale, and on the Discussion that demonstrates scientiﬁc worth
Emphasis is on the data and how they were obtained, i.e.
Methods and Results
Space is limited—selective results are presented Space is not limited
Impact factor affects editorial policy Impact factor is unimportant
Provides access to a small amount of information Provides access to a large amount of information
Paper and electronic Electronic only
Lag time 2–4 months Lag time weeks
Publishes monthly Publishes when MS processed
Subscriber pays Author pays
Subscriber reads or scans the journal User searches for relevant information
Access limited to subscribers Open access
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be performed ethically and approved by the
authors’ institutional review board or its
equivalent.
• Studies are of high quality with the methods and
results fully described. Weaknesses and limita-
tions are acknowledged.
• Information is free of bias.
Given the emphasis of the Archives on data, the
emphasis of papers will be on the Methods and
Results sections. The Introduction can be concise;
a few sentences will sufﬁce to state the objectives
of the study. The Discussion will be brief without
speculation or opinion and should highlight the
limitations of the study. A Conclusion is not
required. The focus of Archives of Drug Information
is on presenting data, not opinion about what the
data might mean.
Moving from “On-ﬁle” to “Online”
Making the results of studies freely available is not
only ethical and good scientiﬁc citizenship, but
ultimately, also good business. Archives of Drug
Information will allow the pharmaceutical industry
and others to publish the results of studies and
make freely accessible to the public the results of
research studies that would otherwise remain
unavailable “on-ﬁle.”
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